


<b>Product Name</b>	: BK-1361
<b>Cat. No.</b>	: PC-60981
<b>CAS No.</b>	: 1975145-82-4
<b>Molecular Formula</b>	: C <sub>31</sub> H <sub>57</sub> N <sub>11</sub> O <sub>9</sub>
<b>Molecular Weight</b>	: 727.865
<b>Target</b>	: Matrix Metalloproteinase (MMP)
<b>Solubility</b>	: 10 mM in DMSO



## Biological Activity

BK-1361 (BK1361, cyclo-RLsKDK) is a cyclic peptide with RLsKDK (s=D-serine) that functions as a potent, selective inhibitor of **ADAM8** with IC<sub>50</sub> of 120 nM.

BK-1361 displays no significant activity against ADAM 9, 10, 12, 17, as well as MMP-2, -9, and -14 at 10 μM.

BK-1361 inhibits shedding of CD23 with IC<sub>50</sub> of 182 nM in cell-based shedding assays, reduces migration/invasion of pancreatic cancer cells and less ERK1/2 and MMP activation, causes change in cell morphology.

BK-1361 decreases tumour burden and metastasis of implanted pancreatic tumour cells and provides improved metrics of clinical symptoms and survival in Kras(G12D)-driven mouse model of PDAC.

## References

Schlomann U, et al. *Nat Commun.* 2015 Jan 28;6:6175.

Chen J, et al. *Sci Rep.* 2016 Jul 26;6:30451.

Yim V, et al. *Bioorg Med Chem.* 2016 Sep 15;24(18):4032-4037.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com